All patients
Age < 65y (younger) Age > 65y BCLC B BCLC C ECOG 0 ECOG 1 Gender, female Gender, male viral status HBV viral status HCV viral status uninfected
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
hepatocell cancer (HCC), pembrolizumab based treatment vs. non active control, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results KEYNOTE-240, 2020 0.78 [0.61; 1.00]
0.78 [0.61 ; 1.00 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable progression or deaths (PFS)detailed results KEYNOTE-240, 2020 0.72 [0.57; 0.90]
0.72 [0.57 ; 0.90 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable DCRdetailed results KEYNOTE-240, 2020 1.44 [0.95; 2.19]
1.44 [0.95 ; 2.19 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable objective responses (ORR)detailed results KEYNOTE-240, 2020 4.83 [2.02; 11.57]
4.83 [2.02 ; 11.57 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable AE (any grade)detailed results KEYNOTE-240, 2020 2.89 [1.23; 6.77]
2.89 [1.23 ; 6.77 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable AE (grade 3-4)detailed results KEYNOTE-240, 2020 1.26 [0.83; 1.90]
1.26 [0.83 ; 1.90 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable AE leading to death (grade 5)detailed results KEYNOTE-240, 2020 0.48 [0.01; 24.29]
0.48 [0.01 ; 24.29 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results KEYNOTE-240, 2020 2.11 [1.08; 4.13]
2.11 [1.08 ; 4.13 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results KEYNOTE-240, 2020 3.04 [1.32; 6.97]
3.04 [1.32 ; 6.97 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable TRAE (any grade)detailed results KEYNOTE-240, 2020 1.66 [1.09; 2.51]
1.66 [1.09 ; 2.51 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 2.77 [1.36; 5.65]
2.77 [1.36 ; 5.65 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable TRAE leading to death (grade 5)detailed results KEYNOTE-240, 2020 0.96 [0.03; 28.81]
0.96 [0.03 ; 28.81 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Abdominal pain TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 0.48 [0.01; 24.29]
0.48 [0.01 ; 24.29 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 0.48 [0.01; 24.29]
0.48 [0.01 ; 24.29 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Alopecia TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 0.48 [0.01; 24.29]
0.48 [0.01 ; 24.29 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Anaemia TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 0.24 [0.02; 2.64]
0.24 [0.02 ; 2.64 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Arthralgia TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 0.48 [0.01; 24.29]
0.48 [0.01 ; 24.29 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Asthenia TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 0.48 [0.01; 24.29]
0.48 [0.01 ; 24.29 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Colitis TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 1.93 [0.09; 43.05]
1.93 [0.09 ; 43.05 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Constipation TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 0.48 [0.01; 24.29]
0.48 [0.01 ; 24.29 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Cough TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 0.48 [0.01; 24.29]
0.48 [0.01 ; 24.29 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 2.90 [0.14; 58.35]
2.90 [0.14 ; 58.35 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Diabetes TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 0.48 [0.03; 7.71]
0.48 [0.03 ; 7.71 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 0.96 [0.09; 10.69]
0.96 [0.09 ; 10.69 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Dry skin TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 0.48 [0.01; 24.29]
0.48 [0.01 ; 24.29 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Dysgeusia TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 0.48 [0.01; 24.29]
0.48 [0.01 ; 24.29 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Dyspepsia TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 0.48 [0.01; 24.29]
0.48 [0.01 ; 24.29 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Dyspnoea TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 0.48 [0.01; 24.29]
0.48 [0.01 ; 24.29 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Eczema TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 0.48 [0.01; 24.29]
0.48 [0.01 ; 24.29 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Fatigue TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 1.45 [0.15; 14.03]
1.45 [0.15 ; 14.03 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Headache TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 0.48 [0.01; 24.29]
0.48 [0.01 ; 24.29 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 3.88 [0.20; 74.00]
3.88 [0.20 ; 74.00 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 0.48 [0.01; 24.29]
0.48 [0.01 ; 24.29 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 0.96 [0.03; 28.81]
0.96 [0.03 ; 28.81 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 0.96 [0.03; 28.81]
0.96 [0.03 ; 28.81 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Increase AST TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 3.75 [0.85; 16.64]
3.75 [0.85 ; 16.64 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 2.45 [0.53; 11.36]
2.45 [0.53 ; 11.36 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 0.48 [0.01; 24.29]
0.48 [0.01 ; 24.29 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 0.24 [0.01; 7.16]
0.24 [0.01 ; 7.16 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 0.48 [0.01; 24.29]
0.48 [0.01 ; 24.29 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Myalgia TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 0.48 [0.01; 24.29]
0.48 [0.01 ; 24.29 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Myositis TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 0.96 [0.03; 28.81]
0.96 [0.03 ; 28.81 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Nausea TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 0.48 [0.01; 24.29]
0.48 [0.01 ; 24.29 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 0.96 [0.03; 28.81]
0.96 [0.03 ; 28.81 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Peripheral oedema TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 0.48 [0.01; 24.29]
0.48 [0.01 ; 24.29 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 1.93 [0.09; 43.05]
1.93 [0.09 ; 43.05 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Pruritus TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 0.96 [0.03; 28.81]
0.96 [0.03 ; 28.81 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Pyrexia TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 0.48 [0.01; 24.29]
0.48 [0.01 ; 24.29 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Rash TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 0.96 [0.03; 28.81]
0.96 [0.03 ; 28.81 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Severe skin reaction TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 5.87 [0.33; 105.85]
5.87 [0.33 ; 105.85 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 0.48 [0.01; 24.29]
0.48 [0.01 ; 24.29 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 0.48 [0.01; 24.29]
0.48 [0.01 ; 24.29 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 0.48 [0.01; 24.29]
0.48 [0.01 ; 24.29 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Vomiting TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 0.48 [0.01; 24.29]
0.48 [0.01 ; 24.29 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Weight decreased TRAE (grade 3-4)detailed results KEYNOTE-240, 2020 0.96 [0.03; 28.81]
0.96 [0.03 ; 28.81 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Abdominal pain AE (grade 3-4)detailed results KEYNOTE-240, 2020 3.88 [0.20; 74.00]
3.88 [0.20 ; 74.00 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Anaemia AE (grade 3-4)detailed results KEYNOTE-240, 2020 0.42 [0.18; 0.97]
0.42 [0.18 ; 0.97 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Arthralgia AE (grade 3-4)detailed results KEYNOTE-240, 2020 0.48 [0.03; 7.71]
0.48 [0.03 ; 7.71 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Asthenia AE (grade 3-4)detailed results KEYNOTE-240, 2020 0.48 [0.01; 24.29]
0.48 [0.01 ; 24.29 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Back pain AE (grade 3-4)detailed results KEYNOTE-240, 2020 3.88 [0.20; 74.00]
3.88 [0.20 ; 74.00 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Constipation AE (grade 3-4)detailed results KEYNOTE-240, 2020 0.96 [0.03; 28.81]
0.96 [0.03 ; 28.81 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Cough AE (grade 3-4)detailed results KEYNOTE-240, 2020 0.48 [0.01; 24.29]
0.48 [0.01 ; 24.29 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Decreased appetite AE (grade 3-4)detailed results KEYNOTE-240, 2020 2.90 [0.14; 58.35]
2.90 [0.14 ; 58.35 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Diarrhoea AE (grade 3-4)detailed results KEYNOTE-240, 2020 0.64 [0.14; 2.88]
0.64 [0.14 ; 2.88 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Dyspnoea AE (grade 3-4)detailed results KEYNOTE-240, 2020 0.12 [0.01; 2.65]
0.12 [0.01 ; 2.65 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Fatigue AE (grade 3-4)detailed results KEYNOTE-240, 2020 1.70 [0.35; 8.29]
1.70 [0.35 ; 8.29 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Increase AST AE (grade 3-4)detailed results KEYNOTE-240, 2020 1.90 [0.91; 3.94]
1.90 [0.91 ; 3.94 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Increased ALT AE (grade 3-4)detailed results KEYNOTE-240, 2020 2.11 [0.70; 6.39]
2.11 [0.70 ; 6.39 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Nausea AE (grade 3-4)detailed results KEYNOTE-240, 2020 0.96 [0.09; 10.69]
0.96 [0.09 ; 10.69 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Peripheral oedema AE (grade 3-4)detailed results KEYNOTE-240, 2020 0.48 [0.01; 24.29]
0.48 [0.01 ; 24.29 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Pruritus AE (grade 3-4)detailed results KEYNOTE-240, 2020 0.96 [0.03; 28.81]
0.96 [0.03 ; 28.81 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Pyrexia AE (grade 3-4)detailed results KEYNOTE-240, 2020 1.93 [0.09; 43.05]
1.93 [0.09 ; 43.05 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable Rash AE (grade 3-4)detailed results KEYNOTE-240, 2020 1.93 [0.09; 43.05]
1.93 [0.09 ; 43.05 ] KEYNOTE-240, 2020 1 0% 413 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 02:01 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 234,382,40,132,131,133
- treatments: 847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561